Early and Systematic Screening in Chronic Neuropathy

Amyloid Neuropathies, Familial Clinical Trial

— TTR-FAP  

Official title:

Evaluation of a New Diagnostic Approach to Familial Amyloid Neuropathy by Mutation of the TTR Gene in a Population of Idiopathic Chronic Neuropathies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03720275
• Other study ID #: CHUBX 2016/35
• Status: Completed
• Phase: N/A
• Start date: November 27, 2018
• Est. completion date: December 23, 2021

Study information

• Verified date: October 2023
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TTR-FAP is a rare disabling inherited disorder that predominantly affects the peripheral nervous system and the heart. Due to an important phenotypic and genetic heterogeneity, the diagnosis is often delayed, preventing therefore early onset treatment. Our project is to evaluate the prevalence of TTR-FAP in a series of 130 patients with from chronic neuropathy of undetermined aetiology through a systematic screening of TTR mutations.

Description:

Transthyretin familial amyloid polyneuropathy (TTR-FAP) is an autosomal dominant disorder, highly disabling and life-threatening, resulting of transthyretin (TTR) gene mutation. Clinically, TTR FAP is characterized by progressive sensorimotor and dysautonomic neuropathy, usually fatal within a few years. The disease prevalence is highly variable, with a large genotypic and phenotypic heterogeneity. Early and accurate diagnosis remains essential to propose early treatment. New pharmacotherapies have been developed, such as Tafamidis®, and many patients can avoid liver transplant formerly considered as the only therapeutic option. The prevalence of TTR-FAP disease has been previously estimated in series of patients with severe and progressive neuropathy, frequently leading to a delayed diagnosis. TTR-FAP is also easily suspected when neuropathy is associated with cardiac symptoms or dysautonomia.

Currently, genetic testing of TTR-FAP is targeted and is only prescribed to patients in whom the first-line assessment recommended by the High Authority for Health (HAS) did not identify a cause, and on the basis of a worsening of symptoms. An early diagnosis in those cases would allow earlier treatment and monitoring. No data are available about the prevalence of TTR-FAP in populations of patients with from chronic neuropathy of unknown aetiology, through a systematic screening of TTR mutations.

The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.

The patients with a diagnosis of TTR-FAP confirmed during this study will be seen for an additional visit in the Investigating Centre and proposed suitable follow up, treatment and care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: December 23, 2021
• Est. primary completion date: May 27, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients of both sexes presenting chronically (> 3 months):

• neuropathy confirmed by an electroneuromyography

• without obvious etiology (diabetes, alcohol consumption, renal insufficiency, neurotoxic substances intake, family history of diagnosed hereditary neuropathy)

• without anomaly of the following biological examinations: fasting blood glucose, blood count, gamma-glutamyl transferases, average cell volume, transaminases, serum creatinine clearance, C-reactive protein, TSH

• Aged 18 to 90 years Patients giving their free and informed consent to participate, after research information

Exclusion Criteria:

• People placed under the protection of justice.

• Patients who are not affiliated or who are not beneficiaries of a social security scheme

• Patients with chronic neuropathy related to a known etiology

Related Conditions & MeSH terms

• Amyloid Neuropathies
• Amyloid Neuropathies, Familial
• Amyloidosis
• Peripheral Nervous System Diseases

Intervention

Genetic:
• Systematic screening of TTR mutations
The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.

Locations

Country	Name	City	State
France	Reference center for neuromuscular diseases	Bordeaux

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Bordeaux	University of Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnosis of TTR-FAP	Proportion of TTR-FAP in the 130 patients with chronic neuropathy of unknown aetiology	Genetic analyzes will be performed every three months from the first inclusion
Secondary	Age of patient at diagnosis		at the inclusion visit
Secondary	History of dysautonomias	History of dysautonomias at the interview	at the inclusion visit
Secondary	Signs of dysautonomias	signs of dysautonomias at the interview	at the inclusion visit
Secondary	Weight of patient	weight	at the inclusion visit
Secondary	Height of patient	height	at the inclusion visit
Secondary	Motor deficit of the lower limbs evaluated by a subscore of the Neuropathy Impairment Scale (NIS)	The Motor deficit of the lower limbs will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the NIS scale is 244 points. The motor sub score, including the evaluation of the upper and lower limbs, is scored on 192 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 4 points.	at the inclusion visit
Secondary	Motor deficit of the upper limbs evaluated by a subscore of the Neuropathy Impairment Scale (NIS)	The Motor deficit of the upper limbs will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 244 points. The motor sub score, including the evaluation of the upper and lower limbs, is scored on 192 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 4 points.	at the inclusion visit
Secondary	Sensory deficit evaluated by a subscore of the Neuropathy Impairment Scale (NIS)	The Sensory deficit will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 244 points. The sensory sub score is scored on 20 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 2 points.	at the inclusion visit
Secondary	Presence / Absence of reflexes osteo-tendinous evaluated by a subscore of the Neuropathy Impairment Scale (NIS)	The Presence/Absence of reflexes osteo-tendinous will be assessed through a sub score of the Neuropathy Impairment Scale (NIS). The maximum score on the scale is 88 points. The reflexes sub score is scored on 8 points. This scale allows to obtain a quantification of the clinical examination. Each item is evaluated between 0 and 2 points.	at the inclusion visit
Secondary	Presence of orthostatic hypotension	Blood pressure measurement by the nurse	at the inclusion visit
Secondary	Dysautonomia score	Score at the clinical scale assessing autonomic dysfunction according to 5 modalities: orthostatic hypotension, high digestive motor disorders, low digestive motor disorders, vesicosphincteric disorders, erectile dysfunction	at the inclusion visit
Secondary	Rasch-built Overall Disability Scale (RODS) score	Score at the RODS, a functional scale that captures daily activity and social participation limitations in patients affected by polyneuropathy (self-questionnaire)	at the inclusion visit
Secondary	Overall Neuropathy Limitations Scale (ONLS) score	The ONLS is a validated neuropathy functional scale evaluating the performance of upper and lower cells. The upper limbs sub score is scored on 5 points and the lower limbs sub score is scored on 7 points. The scale thus ranges from 0 (no disability) to 12 points (disability maximum)	at the inclusion visit
Secondary	Electroneuromyography findings (ENMG): axonal, demyelinating or mixed neuropathy).		at the inclusion visit